Curaleaf Holdings’ Valuation following Its Q3 Results

By

Updated

Curaleaf Holdings’ valuation

In this article, we’ll discuss Curaleaf Holdings’ (CURLF) valuation as of November 27 and its comparison with its peers, including WeedMD (WDDMF), Trulieve (TCNNF), and Maricann (MRRCF).

The chart above compares Curaleaf Holdings’ valuation multiples with those of its peers. Let’s explore the valuation multiples and market caps of Curaleaf and a few of its competitors.

Article continues below advertisement

Forward PE

Curaleaf was trading at a forward PE multiple of ~103.8x on November 26 compared to the industry average of ~44.5x, while its competitor Trulieve (TCNNF) was trading at a forward PE multiple of 21.4x.

Forward EV-to-EBITDA

Since analysts expect Curaleaf’s EBITDA to be negative in the coming months, its forward EV-to-EBITDA (enterprise value-to-EBITDA) multiple is negative. Competitors WeedMD and Maricann are trading at forward EV-to-EBITDA multiples of 6.7x and 20.8x, respectively.

Market cap

Curaleaf Holdings’ market cap as of November 27 is $2.14 billion, and it has 335.1 million shares outstanding in OTC markets. About 99.7% of these shares are free floating. Also, the top ten shareholders hold ~0.31% of the company’s total shares.

The market caps of WeedMD, Trulieve, and Maricann are $121.0 million, $94.7 million, and $195.2 million, respectively.

The Horizons Marijuana Life Sciences ETF (HMMJ) invests in companies in the cannabis industry. It holds ~0.8% in Maricann and 0.5% in WeedMD.

Advertisement

More From Market Realist